| |
r-axSpA patients (n = 30)
|
Healthy Donors (n = 32)
|
P
|
|---|
|
Clinical parameters
|
|
Women/men, n/n
|
5/25
|
10/22
|
0.180
|
|
Age, y
|
46.40 ± 2.45
|
41.06 ± 1.77
|
0.080
|
|
BASDAI
|
4.42 ± 0.45
|
…
| |
|
BASFI
|
4.73 ± 0.61
|
…
| |
|
BASMI
|
3.22 ± 0.31
|
…
| |
|
mSASSS
|
19.16 ± 3.86
|
…
| |
|
Disease duration, y
|
13.23 ± 2.07
|
…
| |
|
Extra-articular manifestations
|
|
➣ Uveitis
|
0/30
|
0/32
| |
|
➣ Psoriasis
|
0/30
|
0/32
| |
|
➣ IBD
|
0/30
|
0/32
| |
|
Laboratory parameters
|
|
HLA-B27 (%)
|
26/30 (86.67%)
|
…
| |
|
CRP†, nmol/L
|
122.57 ± 31.38
|
13.62 ± 3.25
|
< 0.001
|
|
ESR†, mm/h
|
19.84 ± 4.09
|
7.48 ± 1.00
|
0.006
|
|
TNF-α, pg/mL
|
10.89 ± 1.82
|
4.02 ± 1.20
|
0.021
|
|
IL-1β, pg/mL
|
2.46 ± 0.22
|
1.57 ± 0.27
|
0.047
|
|
Treatments
|
|
NSAIDs (%)
|
28/30 (93.33%)
|
…
| |
|
Sulfasalazine (%)
|
2/30 (6.67%)
|
…
| |
- Values are presented as mean ± SEM. The data were analyzed using an Independent Samples t test or a Mann-Whitney U test to evaluate statistical significance between r-axSpA patients and healthy donors. †Non-normally distributed data. BASDAI indicates Bath Ankylosing Spondylitis Disease Activity Index; BASFI, Bath Ankylosing Spondylitis Functionality Index; BASMI, Bath Ankylosing Spondylitis Metrology Index; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; HLA, human leukocyte antigen; IBD, inflammatory bowel disease; IL, interleukin; mSASSS, modified Stoke Ankylosing Spondylitis Spine Score; NSAIDs, non-steroidal anti-inflammatory drugs; r-axSpA, radiographic axial spondyloarthritis; TNF, tumor necrosis factor
